IDA blend vs Switzerland: Access to anti-retroviral drugs, male
IDA blend
74.0%
in 2024
Switzerland
90.0%
in 2023
IDA blend rank
14th
Switzerland rank
13th
Access to anti-retroviral drugs, male over time
- IDA blend
- Switzerland
How they compare
Switzerland currently reports 90.0% against 74.0% in IDA blend, a difference of 16.0%.
That makes Switzerland's figure about 1.2 times IDA blend's.
Across all 24 years both countries report, Switzerland has been ahead every year.
IDA blend ranks 14th and Switzerland ranks 13th of 19 groups.
Switzerland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | IDA blend | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.5% | 50.0% | 44.5% | Switzerland |
| 2010s | 38.5% | 79.2% | 40.7% | Switzerland |
| 2020s | 66.1% | 90.2% | 24.1% | Switzerland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, IDA blend or Switzerland?
- Switzerland, at 90.0% against 74.0% in IDA blend as of 2023.
- What is the difference in access to anti-retroviral drugs, male between IDA blend and Switzerland?
- 16.0%, with Switzerland ahead.
- How many years of comparable data are there for IDA blend and Switzerland?
- 24 years are reported by both, from 2000 to 2023.
- How do IDA blend and Switzerland rank globally for access to anti-retroviral drugs, male?
- IDA blend ranks 14th and Switzerland ranks 13th of 19 groups.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.